Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUET-CC: QL1706 plus sequential chemoradiotherapy in locally advanced cervical cancer
ChiCTR2500109700Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in Cervical Cancer (CC), sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoint: Objective response rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500109700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109700.